|
1
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Glozak MA and Seto E: Histone deacetylases
and cancer. Oncogene. 26:5420–5432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song J, Noh JH, Lee JH, Eun JW, Ahn YM,
Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY and Nam SW: Increased
expression of histone deacetylase 2 is found in human gastric
cancer. APMIS. 113:264–268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba
H, Kohnoe S, Yonemasu H, Hachitanda Y, Okamura T and Sugimachi K:
Histone H4 acetylation and histone deacetylase 1 expression in
esophageal squamous cell carcinoma. Oncol Rep. 10:333–338.
2003.PubMed/NCBI
|
|
5
|
Giannini R and Cavallini A: Expression
analysis of a subset of coregulators and three nuclear receptors in
human colorectal carcinoma. Anticancer Res. 25:4287–4292.
2005.PubMed/NCBI
|
|
6
|
Waltregny D, North B, Van Mellaert F, de
Leval J, Verdin E and Castronovo V: Screening of histone
deacetylases (HDAC) expression in human prostate cancer reveals
distinct class I HDAC profiles between epithelial and stromal
cells. Eur J Histochem. 48:273–290. 2004.PubMed/NCBI
|
|
7
|
Bartling B, Hofmann HS, Boettger T, Hansen
G, Burdach S, Silber RE and Simm A: Comparative application of
antibody and gene array for expression profiling in human squamous
cell lung carcinoma. Lung Cancer. 49:145–154. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garber K: Purchase of Aton spotlights HDAC
inhibitors. Nat Biotechnol. 22:364–365. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duvic M and Vu J: Vorinostat: A new oral
histone deacetylase inhibitor approved for cutaneous T-cell
lymphoma. Expert Opin Investig Drugs. 16:1111–1120. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grant C, Rahman F, Piekarz R, Peer C, Frye
R, Robey RW, Gardner ER, Figg WD and Bates SE: Romidepsin: A new
therapy for cutaneous T-cell lymphoma and a potential therapy for
solid tumors. Expert Rev Anticancer Ther. 10:997–1008. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Poole RM: Belinostat: First global
approval. Drugs. 74:1543–1554. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JH, Choy ML and Marks PA: Mechanisms
of resistance to histone deacetylase inhibitors. Adv Cancer Res.
116:39–86. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Y, Dong M, Hong X, Zhang W, Feng J,
Zhu J, Yu L, Ke X, Huang H, Shen Z, et al: Results from a
multicenter, open-label, pivotal phase II study of chidamide in
relapsed or refractory peripheral T-cell lymphoma. Ann Oncol.
26:1766–1771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ning ZQ, Li ZB, Newman MJ, Shan S, Wang
XH, Pan DS, Zhang J, Dong M, Du X and Lu XP: Chidamide
(CS055/HBI-8000): A new histone deacetylase inhibitor of the
benzamide class with antitumor activity and the ability to enhance
immune cell-mediated tumor cell cytotoxicity. Cancer Chemother
Pharmacol. 69:901–909. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong M, Ning ZQ, Xing PY, Xu JL, Cao HX,
Dou GF, Meng ZY, Shi YK, Lu XP and Feng FY: Phase I study of
chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in
patients with advanced solid tumors and lymphomas. Cancer Chemother
Pharmacol. 69:1413–1422. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K,
Yue XP, Nie LP, Wan J, Lu XP, Zhang W and Ning ZQ: Non-toxic dose
chidamide synergistically enhances platinum-induced DNA damage
responses and apoptosis in non-small-cell lung cancer cells. Biomed
Pharmacother. 68:483–491. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu L, Qiu S, Liu Y, Liu Z, Zheng Y, Su X,
Chen B and Chen H: Chidamide and 5-flurouracil show a synergistic
antitumor effect on human colon cancer xenografts in nude mice.
Neoplasma. 63:193–200. 2016.PubMed/NCBI
|
|
19
|
Wang H, Guo Y, Fu M, Liang X, Zhang X,
Wang R, Lin C and Qian H: Antitumor activity of Chidamide in
hepatocellular carcinoma cell lines. Mol Med Rep. 5:1503–1508.
2012.PubMed/NCBI
|
|
20
|
Dedes KJ, Dedes I, Imesch P, von Bueren
AO, Fink D and Fedier A: Acquired vorinostat resistance shows
partial cross-resistance to ‘second-generation’ HDAC inhibitors and
correlates with loss of histone acetylation and apoptosis but not
with altered HDAC and HAT activities. Anticancer Drugs. 20:321–333.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fiskus W, Rao R, Fernandez P, Herger B,
Yang Y, Chen J, Kolhe R, Mandawat A, Wang Y, Joshi R, et al:
Molecular and biologic characterization and drug sensitivity of
pan-histone deacetylase inhibitor-resistant acute myeloid leukemia
cells. Blood. 112:2896–2905. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiao JJ, Huang Y, Dai Z, Sadée W, Chen J,
Liu S, Marcucci G, Byrd J, Covey JM, Wright J, et al:
Chemoresistance to depsipeptide FK228
[(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone]
is mediated by reversible MDR1 induction in human cancer cell
lines. J Pharmacol Exp Ther. 314:467–475. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamada H, Arakawa Y, Saito S, Agawa M,
Kano Y and Horiguchi-Yamada J: Depsipeptide-resistant KU812 cells
show reversible P-glycoprotein expression, hyper-acetylated
histones, and modulated gene expression profile. Leukemia Res.
30:723–734. 2006. View Article : Google Scholar
|
|
24
|
Juengel E, Makarević J, Tsaur I, Bartsch
G, Nelson K, Haferkamp A and Blaheta RA: Resistance after chronic
application of the HDAC-inhibitor valproic acid is associated with
elevated Akt activation in renal cell carcinoma in vivo. PLoS One.
8:e531002013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu Y, Das K, Wu J, Lee MH and Tan P: RNH1
regulation of reactive oxygen species contributes to histone
deacetylase inhibitor resistance in gastric cancer cells. Oncogene.
33:1527–1537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Robey RW, Chakraborty AR, Basseville A,
Luchenko V, Bahr J, Zhan Z and Bates SE: Histone deacetylase
inhibitors: Emerging mechanisms of resistance. Mol Pharm.
8:2021–2031. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakagawa M, Oda Y, Eguchi T, Aishima S,
Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M and Tsuneyoshi
M: Expression profile of class I histone deacetylases in human
cancer tissues. Oncol Rep. 18:769–774. 2007.PubMed/NCBI
|
|
28
|
Jamaladdin S, Kelly RD, O'Regan L, Dovey
OM, Hodson GE, Millard CJ, Portolano N, Fry AM, Schwabe JW and
Cowley SM: Histone deacetylase (HDAC) 1 and 2 are essential for
accurate cell division and the pluripotency of embryonic stem
cells. Proc Natl Acad Sci USA. 111:pp. 9840–9845. 2014, View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU,
Joo HJ and Kim DY: Expression profile of histone deacetylase 1 in
gastric cancer tissues. Jpn J Cancer Res. 92:1300–1304. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Korfei M, Skwarna S, Henneke I, MacKenzie
B, Klymenko O, Saito S, Ruppert C, von der Beck D, Mahavadi P,
Klepetko W, et al: Aberrant expression and activity of histone
deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax.
70:1022–1032. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Seigneurin-Berny D, Verdel A, Curtet S,
Lemercier C, Garin J, Rousseaux S and Khochbin S: Identification of
components of the murine histone deacetylase 6 complex: Link
between acetylation and ubiquitination signaling pathways. Mol Cell
Biol. 21:8035–8044. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu D, Zhou P, Zhang L, Zheng Y and He F:
HPV16 activates the promoter of Oct4 gene by sequestering HDAC1
from repressor complex to target it to proteasomal degradation. Med
Hypotheses. 79:531–534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cao D, Bromberg PA and Samet JM: COX-2
expression induced by diesel particles involves chromatin
modification and degradation of HDAC1. Am J Respir Cell Mol Biol.
37:232–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chuang JY and Hung JJ: Overexpression of
HDAC1 induces cellular senescence by Sp1/PP2A/pRb pathway. Biochem
Biophys Res Commun. 407:587–592. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang D, Ochi N, Takigawa N, Tanimoto Y,
Chen Y, Ichihara E, Hotta K, Tabata M, Tanimoto M and Kiura K:
Establishment of pemetrexed-resistant non-small cell lung cancer
cell lines. Cancer Lett. 309:228–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Li H, Ren Y, Zou S, Fang W, Jiang
X, Jia L, Li M, Liu X, Yuan X, et al: Targeting HDAC with a novel
inhibitor effectively reverses paclitaxel resistance in non-small
cell lung cancer via multiple mechanisms. Cell Death Dis.
7:e20632016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gong K, Xie J, Yi H and Li W: CS055
(Chidamide/HBI-8000), a novel histone deacetylase inhibitor,
induces G1 arrest, ROS-dependent apoptosis and differentiation in
human leukaemia cells. Biochem J. 443:735–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sorenson CM and Eastman A: Mechanism of
cis-diamminedichloroplatinum(II)-induced cytotoxicity: Role of G2
arrest and DNA double-strand breaks. Cancer Res. 48:4484–4488.
1988.PubMed/NCBI
|
|
40
|
Santi DV, McHenry CS and Sommer H:
Mechanism of interaction of thymidylate synthetase with
5-fluorodeoxyuridylate. Biochemistry. 13:471–481. 1974. View Article : Google Scholar : PubMed/NCBI
|
